Hanmi Pharm said on Jan. 16 that it attended the 38th JP Morgan Healthcare Conference held in San Francisco from Jan. 13 to 15 and announced the company’s 2020 vision and major R&D strategies.
This year's event was attended by major executives in charge of R&D and global business, including Vice Chairman Lee Kwan-soon, CEO Kwon Se-chang, and Seo Gwi-hyun, head of the research center.
Delivering a speech, Kwon introduced a number of key pipelines to lead the company’s new challenges in 2020. Kwon, who cited eight candidate materials for new drugs as a key task among 29 pipelines, stressed that he will focus on generating performance, including additional license outs.
Among the key tasks that Kwon picked were HM15211 (LAPSTriple Agonist), which targets NASH, and such antiobestic drugs as HM12525A (LAPSGlucagon/GLP-1 Dual Agonist), and HM15136 (LAPSGlucagon Analog), the so-called first-in-class candidates for new drugs.
The differentiated innovation of the NASH treatment HM15211 (LAPSTriple Agonist) announced by Kwon drew keen attention from participants.
Up to now, NASH, a chronic liver disease that has no cure, is critical to improve multiple indicators simultaneously, including fatty liver, inflammation and fiber, and HM15211 has been identified as having several effects, including rapid and strong reduction of fatty liver, in the clinical test 1 of the MAD (Mautiple Ascending Dose Study).
Hanmi Pharm plans to launch the global clinical trial 2 of HM15211 for NASH patients.